Search tips
Search criteria

Results 1-2 (2)

Clipboard (0)

Select a Filter Below

more »
Year of Publication
Document Types
1.  Time course of inflammatory cytokines in acute ischemic stroke patients and their relation to inter-alfa trypsin inhibitor heavy chain 4 and outcome 
Biomarker for prognosis of stroke is urgently needed for the management of acute ischemic stroke (AIS) patients.
To evaluate the course of inflammatory cytokines in AIS patients and its comparison with inter-alfa trypsin inhibitor heavy chain 4 (ITIH4) and outcome after AIS.
Materials and Methods:
A panel of 12 inflammatory cytokines and ITIH4 were estimated in serial blood samples collected at admission, 24 h, 48 h, 72 h, 144 h and at discharge of AIS patients (n = 5).
Out of the 12 cytokines, only interleukin (IL)-2, tumor necrosis factor-alfa (TNF-α), IL-10, IL-6, IL-1B and IL-8 were in the measurable range of the kit (10 pg/mL). We found high IL-2 at admission, which decreased (P < 0.05) in the follow-up samples. TNF-α initially increases (P < 0.05) at 24 h followed by gradual decrease (P < 0.05) after 72 h. IL-10 decreases initially (P < 0.05) till 72 h as compared with its level at admission and then increases (P < 0.05) after 144 h. Similarly, ITIH4 was down-regulated in the early 72 h followed by further increase with improvement of the patient. ITIH4 correlates with IL-10 and computed tomography scan infarct volume. Serum IL-6, IL-1B and IL-8 increased in the AIS patients, but did not show any pattern.
Serial measurement of IL-10, IL-2 and TNF-α and ITIH4 may be useful for the follow-up of clinical outcome after AIS.
PMCID: PMC3424794  PMID: 22919189
Acute ischemic stroke; cytokine; inter-alfa trypsin inhibitor heavy chain 4; prognosis
2.  Prognostic significance of ischemia-modified albumin in acute ischemic stroke patients: A preliminary study 
Annals of Neurosciences  2011;18(1):5-7.
Ischemia-modified albumin (IMA) is a sensitive marker of ischemic event. However, limited studies are available regarding role of IMA in acute ischemic stroke (AIS).
The aim of this study was to evaluate time course of IMA in AIS patient to validate its prognostic value.
IMA level was estimated in serum samples collected from five AIS patients at admission, 24hrs, 48hrs, 72hrs, and 144hrs after admission and also from five control subjects.
There was significant (p<0.05) increase in IMA level in AIS samples at admission, 24hrs, 48hrs and 144hrs respectively when compared with control. On comparing IMA levels in follow up AIS samples with that of admission value we found that it decreased in follow-up samples till 72hrs, and significant (p<0.05) decrease was observed at 24hrs and 72hrs.
Findings shows that follow up estimation of IMA level in AIS may help in the prediction of the clinical status and outcome.
PMCID: PMC4117019  PMID: 25205910
Acute ischemic stroke; Prognosis; Ischemia modified albumin; Biomarker; Serum marker

Results 1-2 (2)